Armata Pharmaceuticals Inc. (ARMP)
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
XTL Biopharmaceuticals Acquires 85% of Beyond Airs Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
Anavex Joins ACCESS-AD, Major Initiative Funded by the EU Commission, through Clinical Evaluation of Blarcamesine as Part of Precision Medicine in AD
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026